Validity testing of patient objections to acceptance of tamper-resistant opioid formulations

References

• Purdue Pharma LPTo determine the fasting bioequivalence of reformulated OXY tablets and original OxyContin® (OXY) tabletsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated May 6, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00801788. NLM identifier: NCT00801788Accessed February 21, 2013
   Google Scholar
• Purdue Pharma LPTo determine the fed bioequivalence of reformulated OXY tablets and original OxyContin® (OXY) tabletsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated October 7, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01101178. NLM identifier: NCT01101178Accessed February 21, 2013
   Google Scholar
• Purdue Pharma LPA study to determine the fasting bioequivalence of reformulated OXY tablets and original OxyContin® (OXY) tabletsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated May 17, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01100086. NLM identifier: NCT01100086Accessed February 21, 2013
   Google Scholar
• Purdue Pharma LPA study to determine the fed bioequivalence of reformulated OXY tablets and original OxyContin® (OXY) tabletsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated April 13, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01099709. NLM identifier: NCT01099709Accessed February 21, 2013
   Google Scholar
• Purdue Pharma LPA study to determine the fed bioequivalence of reformulated OXY tablets and original OxyContin® (OXY) tabletsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated May 6, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01100320. NLM identifier: NCT01100320Accessed February 21, 2013
   Google Scholar
• BlackRCoplanPCassidyTEffects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinal surveillance networkJ Pain2012134SS58
   Google Scholar
• CassidyTCoplanPBlackRAChilcoatHBudmanSHButlerSInitial findings on abuse rates and routes of administration following introduction of reformulated OxyContin® in a sentinel surveillance system of patients in substance use treatmentProceedings of PAINWeekSeptember 7–11, 2011Las Vegas, NV, USA
   Google Scholar
• CiceroTJEllisMSSurrattHLEffect of abuse-deterrent formulation of OxyContinN Engl J Med2012367218718922784140
   PubMed Web of Science ®Google Scholar
• Purdue Pharma LPDear Healthcare ProfessionalStamfordPurdue Pharma LP Available from: http://www.purduepharma.com/pdfs/dearHCPletter.pdfAccessed February 21, 2013
   Google Scholar
• Purdue Pharma LPFDA Advisory Committee on Reformulated OxyContinStamfordPurdue Pharma LP2009 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM249272.pdfAccessed March 6, 2013
   Google Scholar
• ButlerSFBenoitCBudmanSHDevelopment and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusersHarm Reduct J20063516457713
   PubMedGoogle Scholar
• SchoedelKAMcMornSChakrabortyBPottsSLZerbeKSellersEMPositive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid usersJ Opioid Manag20117317919221823549
   PubMedGoogle Scholar
• Aetna Inc2012 Aetna Preferred Drug Guide: 4-Tier/Open Formulary PlanHartfordAetna Health Inc2011 Available from: http://media.mcclatchy.com/static/healthworks/pdf/11/20124Tier.pdfAccessed March 6, 2013
   Google Scholar
• United Healthcare and Affiliated CompaniesUnited Healthcare 2013 Prescription Drug ListMinneapolisUnited Healthcare2013 Available from: https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Pharmacy%20Resources/PDL_Phys_Bk.pdfAccessed March 6, 2013
   Google Scholar
• Kaiser PermanenteKaiser Permanente 2013 Comprehensive FormularyRockvilleKaiser Permanente2013 Available from: https://healthy.kaiserpermanente.org/static/health/en-us/pdfs/nat/Medicare_2013_NAT/comprehensive_formulary.pdfAccessed February 21, 2013
   Google Scholar
• Medco Health Solutions IncMedco Medicare Prescription Plan® (PDP) 2012 Formulary (List of Covered Drugs)Franklin LakesMedco Health Solutions Inc2011 Available from: http://www.q1medicare.com/2012/content/includes/pdpPlanMaterials/Medco-2012_Value_Formulary.pdfAccessed February 21, 2013
   Google Scholar
• Aetna IncAetna Medicare 2012 Formulary: List of Covered DrugsHartfordAetna Health Inc2011 Available from: http://www.aetnamedicare.com/documents/individual/2012/formularies/2012_medicare_preferred_drug_list.pdfAccessed March 6, 2013
   Google Scholar
• Anthem Blue Cross Life and Health Insurance Company (Anthem)Blue Cross MedicareRx Gold (PDP): 2012 Formulary (List of Covered Drugs)Woodland HillsAnthem Blue Cross2011 Available from: http://www.anthem.com/ca/shop/content/olspublic/pdf/2012/english/PDP_ComForm_MRx_Gold_CA.pdfAccessed February 21, 2013
   Google Scholar
• Ontario Ministry of Health and Long-Term CareChange in Funding Status of Oxycodone Controlled Release Tablet – (Discontinuation of OxyContin and Introduction of OxyNEO)TorontoOntario Ministry of Health and Long-Term Care2012 Available from: http://www.ocfp.on.ca/docs/annual-scientific-assembly/important-notice-regarding-change-in-funding-status-of-oxycodone-controlled-release-tablet.pdf?sfvrsn=0Accessed March 6, 2013
   Google Scholar
• Purdue PharmaInformation for Vermont Prescribers of Prescription Drugs: OxyContin® (Oxycodone HCl Controlled-Release) TabletsStamfordPurdue Pharma LP2013 Available from: http://www.purduepharma.com/vermont/Oxycontin_vt.pdfAccessed February 21, 2013
   Google Scholar
• Healthcaregov [webpage on the Internet]Healthcare blog: what is the donut hole?WashingtonUS Department of Health and Human Services2010 Available from: http://www.healthcare.gov/blog/2010/08/donuthole.htmlAccessed March 6, 2013
   Google Scholar
• BenedekIHJobesJXiangQFiskeWDBioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended releaseDrug Des Devel Ther20115455463
   PubMed Web of Science ®Google Scholar
• FiskeWDJobesJXiangQChangSCBenedekIHThe effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tabletsJ Pain2012131909922208805
   PubMed Web of Science ®Google Scholar
• Janssen PharmaceuticalsNUCYNTA® ER (tapentadol). Full Prescribing InformationTitusvilleJanssen Pharmaceuticals, Inc2012 Available from: http://www.janssenmedicalinformation.com/assets/pdf/products/files/NUCYNTA%20ER/pi/ENC-010401-11.pdfAccessed February 21, 2013
   Google Scholar
• RappaportRADivision director’s review and summary basis for approval NDA 200533FDAgov [website on the Internet]Silver Spring, MDUS Food and Drug Administration2011 [updated August 25, 2011]. US Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200533Orig1s000SumR.pdfAccessed February 21, 2013
   Google Scholar
• CassidyTAMcNaughtonECButlerSFBudmanSHChanges in prescription opioid abuse after introduction of an abuse deterrent opioid formulationProceedings of PAINWeekSeptember 4–7, 2012Las Vegas, NV, USA
   Google Scholar
• BartholomaeusJArkenau-MarićEGaliaEOpioid extended-release tablets with improved tamper-resistant propertiesExpert Opin Drug Deliv20129887989122690792
   PubMed Web of Science ®Google Scholar
• Purdue Pharma LPOxyContin® (Oxycodone HCl Controlled-Release Tablets). Full Prescribing InformationStamfordPurdue Pharma LP2010 Available from: http://app.purduepharma.com/xmlpublishing/pi.aspx?id=oAccessed February 21, 2013
   Google Scholar
• SmithMLHughesROLevineBDickersonSDarwinWDConeEJForensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometryJ Anal Toxicol199519118267536861
   PubMed Web of Science ®Google Scholar
• SlatkinNEOpioid switching and rotation in primary care: implementation and clinical utilityCurr Med Res Opin20092592133215019601703
   PubMed Web of Science ®Google Scholar
• ButlerSFFernandezKCChangAMeasuring attractiveness for abuse of prescription opioidsPain Med2010111678020002325
   PubMed Web of Science ®Google Scholar